Skip to main
  1. Stocks
  2. Intellia Therapeutics
  3. Forecast
NTLA

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics (NTLA) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 25%
Buy 19%
Hold 38%
Sell 13%
Strong Sell 6%

Bulls say

Intellia Therapeutics is supported by a de-risked HAE franchise, as lonvo-z’s Phase 3 HAELO data showed an 87% reduction in mean monthly attacks versus placebo, with 62% of patients attack-free over the six-month period and no advisory committee meeting planned. FDA acceptance of the BLA with Priority Review and a March 10, 2027 PDUFA date meaningfully clarifies the path to what could become the first approved in vivo CRISPR therapy, while also establishing a major regulatory precedent for the platform. Financially, the company’s new $400M OrbiMed facility, including a potential additional $75M draw after approval, reduces near-term dilution risk and aligns liquidity with launch execution and future revenue milestones.

Bears say

Intellia Therapeutics is burdened by a still-immature CRISPR/Cas9 platform, with no approved genome-editing product and limited clinical trial experience, leaving the company exposed to outsized disappointment if development or efficacy data weaken. Its dependence on uncertain third-party intellectual property and partnerships with Novartis and Regeneron adds strategic risk, while any clinical setback could damage confidence in both the pipeline and the broader technology. Although lonvo-z has FDA Priority Review with a March 10, 2027 PDUFA date and forecast revenue of $8.8MM in 2027, $33.8MM in 2028, and $82.4MM in 2029, the need for additional equity financing implies dilution risk and commercialization remains limited by breakthrough attacks in 38% of patients.

Intellia Therapeutics (NTLA) has been analyzed by 16 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 13% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Intellia Therapeutics (NTLA) Analyst Forecast & Price Prediction

Get the latest Intellia Therapeutics (NTLA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Intellia Therapeutics (NTLA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Intellia Therapeutics (NTLA) Forecast

Analysts have given Intellia Therapeutics (NTLA) a Hold based on their latest research and market trends.

According to 16 analysts, Intellia Therapeutics (NTLA) has a Hold consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Intellia Therapeutics (NTLA)


Intellia Therapeutics (NTLA) Analyst Forecast & Price Prediction

Get the latest Intellia Therapeutics (NTLA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Intellia Therapeutics (NTLA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NTLA stock data and trends